Santen Pharmaceutical (OTCMKTS:SNPHY) Sees Unusually-High Trading Volume – Time to Buy?

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) saw unusually-high trading volume on Friday . Approximately 31,899 shares changed hands during trading, an increase of 94% from the previous session’s volume of 16,471 shares.The stock last traded at $10.43 and had previously closed at $10.6750.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

Santen Pharmaceutical Trading Down 6.1%

The firm has a fifty day moving average price of $10.96 and a 200 day moving average price of $10.66. The firm has a market cap of $3.22 billion and a PE ratio of 0.10.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.